Overview

• A randomized placebo-crossover trial of about 30 children with recessive dystrophic epidermolysis bullosa found intravenous CORDStrom infusions safe and associated with reduced blistering and inflammation in some patients
• The strongest benefits were observed in children under 10 and those with intermediate-type disease, indicating a variable response by age and subtype
• Families reported measurable quality-of-life gains, including faster wound healing, less itching, fewer dressing changes and increased participation in daily activities
• Following publication in eClinicalMedicine, INmuneBio agreed to supply CORDStrom free for one year with two infusions every four months for trial participants
• A 12-month open-label follow-up has begun to gather longer-term data and the manufacturer is pursuing regulatory approval for broader clinical use